KR20230069161A - 아밀로이드증의 치료 방법 - Google Patents

아밀로이드증의 치료 방법 Download PDF

Info

Publication number
KR20230069161A
KR20230069161A KR1020237012401A KR20237012401A KR20230069161A KR 20230069161 A KR20230069161 A KR 20230069161A KR 1020237012401 A KR1020237012401 A KR 1020237012401A KR 20237012401 A KR20237012401 A KR 20237012401A KR 20230069161 A KR20230069161 A KR 20230069161A
Authority
KR
South Korea
Prior art keywords
antibody
subject
amyloidosis
dose
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237012401A
Other languages
English (en)
Korean (ko)
Inventor
마이클 스펙터
수전 비. 소볼로브-제이네스
마이클 카사이
앤쏘니 에스. 루비닉키
제시카 지. 라비옹
Original Assignee
시일럼 바이오사이언시즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시일럼 바이오사이언시즈, 인크. filed Critical 시일럼 바이오사이언시즈, 인크.
Publication of KR20230069161A publication Critical patent/KR20230069161A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
KR1020237012401A 2020-09-14 2021-09-14 아밀로이드증의 치료 방법 Pending KR20230069161A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063078258P 2020-09-14 2020-09-14
US63/078,258 2020-09-14
US202063116100P 2020-11-19 2020-11-19
US63/116,100 2020-11-19
US202163176015P 2021-04-16 2021-04-16
US63/176,015 2021-04-16
PCT/US2021/050316 WO2022056484A1 (en) 2020-09-14 2021-09-14 Method of treating amyloidosis

Publications (1)

Publication Number Publication Date
KR20230069161A true KR20230069161A (ko) 2023-05-18

Family

ID=80631942

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237012401A Pending KR20230069161A (ko) 2020-09-14 2021-09-14 아밀로이드증의 치료 방법

Country Status (9)

Country Link
US (1) US20230364228A1 (https=)
EP (1) EP4210753A4 (https=)
JP (1) JP2023541191A (https=)
KR (1) KR20230069161A (https=)
AU (1) AU2021339851A1 (https=)
CA (1) CA3192069A1 (https=)
IL (1) IL301047A (https=)
MX (1) MX2023002997A (https=)
WO (1) WO2022056484A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022346750A1 (en) * 2021-09-14 2024-04-11 Caelum Biosciences, Inc. Method of treating multiple myeloma
CN120322242A (zh) * 2022-09-16 2025-07-15 联邦高等教育系统天普大学 Bag3用于治疗心脏淀粉样变性的方法和用途
WO2025194030A1 (en) 2024-03-15 2025-09-18 Alexion Pharmaceuticals, Inc. Treatment of mayo stage iiib light chain amyloidosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5553963B2 (ja) * 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
US20090028847A1 (en) * 2007-04-12 2009-01-29 Trustees Of Boston University Multiple myeloma and al amyloid immunotherapy targeting immunoglobulin light chains and uses thereof
WO2016189491A1 (en) * 2015-05-28 2016-12-01 Glaxosmithkline Intellectual Property Development Limited Novel formulation
US11382974B2 (en) * 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
PH12021552135A1 (en) * 2019-03-05 2022-08-31 Prothena Biosciences Ltd Methods of treating al amyloidosis

Also Published As

Publication number Publication date
US20230364228A1 (en) 2023-11-16
JP2023541191A (ja) 2023-09-28
AU2021339851A1 (en) 2023-04-13
AU2021339851A8 (en) 2023-04-20
WO2022056484A1 (en) 2022-03-17
CA3192069A1 (en) 2022-03-17
EP4210753A1 (en) 2023-07-19
MX2023002997A (es) 2023-05-11
EP4210753A4 (en) 2025-01-08
IL301047A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
US20220195065A1 (en) Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatment
CN103459595B (zh) 针对人前列腺素e2受体ep4的抗体
KR20230069161A (ko) 아밀로이드증의 치료 방법
CA2899889A1 (en) Administration of an anti-activin-a compound to a subject
KR20230007531A (ko) 아밀로이드 침착 질환의 치료를 위한 방법 및 조성물
JP2012526846A (ja) ループス治療のための方法および組成物
CA3110276A1 (en) Treatment of triple negative breast cancer with targeted tgf-b inhibition
CN118043072A (zh) 治疗多发性骨髓瘤的方法
US20250074981A1 (en) Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer
US20240392028A1 (en) Method of treating multiple myeloma
EP4491194A1 (en) Triple combination drug dosing therapy for head and neck cancer treatment
KR20210142088A (ko) 치료방법
JP2021528399A (ja) 胆道癌を治療する際に使用するための標的ＴＧＦ−β阻害のための投薬計画
EA050760B1 (ru) Способ лечения множественной миеломы
CN116782935A (zh) 治疗淀粉样变性的方法
IL293615A (en) Use of isatuzimab for the treatment of recurrent and/or resistant multiple myeloma
JP2025515344A (ja) 抗ｐｄ－１抗体と抗ｅｇｆｒ抗体との組み合わせ及び頭頸部扁平上皮がんの治療におけるその使用
HK40110052A (zh) 用於治疗癌症的方法和组合物
HK40035170A (en) Methods and compositions for treatment of amyloid deposition diseases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230412

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240913

Comment text: Request for Examination of Application